Integrity Score 374
No Records Found
No Records Found
No Records Found
Source: Washington Post
Novavax, a Maryland biotechnology company that endured delays in developing a coronavirus vaccine, revealed results Monday showing that the world is close to having another shot that prevents illness and death, stops virus variants — and proves easy to store.
The two-shot regimen was 90 percent effective at preventing people from falling ill in a 30,000-person trial conducted when variants had begun to complicate the pandemic in the United States and Mexico.
Vaccinated people were completely protected against severe and even moderate cases of illness. There were no cases of hospitalization or death among people who received the vaccine. The shots also may be the most tolerable yet tested. Side effects included fatigue, headaches and muscle pain, but reactions tended to be less frequent than those triggered by some already authorized vaccines.
“It’s really very impressive,” said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, noting the vaccine was on par with the most effective shots developed during the pandemic. “It’s very important for the world’s population to have, yet again, another highly efficacious vaccine that looks in its trial to have a good safety profile.”
Kathleen Neuzil, professor of vaccinology at the University of Maryland School of Medicine, said she often cautions people not to compare vaccine trials because there are so many differences in how and when they are conducted.
“Once you get to 90 to 100 percent effective, it’s hard to even decipher differences. … The efficacy looks great,” Neuzil said. “We need the manufacturing, obviously, to get it to the world.”